Latest News - Headache & Pain

Thursday, August 16, 2018

Intrathecal Baclofen More Effective Than Oral Medication for Treating Pain in Patients With Poststroke Spasticity

Results from the SISTERS trial (NCT01032239) show that intrathecal administration (ITB Therapy; Medtronic, Dublin, Ireland) of baclofen (Lioresal Intrathecal; Saol Therapeutics, Roswell, GA) is a more…

Read the full story

Monday, July 30, 2018

Breaching the Blood-Brain Barrier: A Potential New Treatment Modality

In a small, yet groundbreaking, clinical trial, MR-guided focused ultrasound (MRgFUS) (ExablateNeuro; Insightec, Miami FL) was used to open the blood-brain barrier (BBB) safely in 5 persons with mild-…

Read the full story

Tuesday, July 03, 2018

Rimegepant Provides Freedom From Pain and Other Symptoms in Phase 3 Clinical Trials

Expanded data from 2 randomized, pivotal phase 3 clinical trials of rimegepant (Biohaven, New Haven, CT), a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist was presented that…

Read the full story

Saturday, June 30, 2018

Addressing the High Impact of Migraine at Work

Initial findings from a large global migraine patient survey involving >11,000 people from 31 countries show migraine is associated with overall work and activity impairment.  The My Migraine …

Read the full story

Friday, June 15, 2018

Ketamine Guidelines for Acute Pain Management Established and Released for the First Time

Intravenous (IV) ketamine has been used to treat acute pain in multiple conditions including as a stand-alone treatment, and as an adjunct to opioids. Ketamine is being used in both inpatient and outp…

Read the full story

Wednesday, June 13, 2018

Atogepant Demonstrates Efficacy and Safety for Prevention of Episodic Migraine

In a phase 2b/3 clinical trial (CGP-MD-01) of the orally administered calcitonin gene-related peptide receptor (CGRP) antagonist, atogepant (Allergan, Ireland), all primary endpoints for all doses and…

Read the full story

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Wednesday, May 23, 2018

New Type of Vertigo Defined That May Be Treatable

Neurologists have defined a new type of vertigo with no known cause (Neurology. 2018:published online May 23). The authors have differentiated this type of vertigo from serious causes of vertigo (eg, …

Read the full story

Wednesday, May 23, 2018

Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Pain

Topline results the first pivotal phase 3 clinical trial of intravenous (IV) tramadol (Avenue Therapeutics, New York, NY) have been released. Enrolled patients were randomized into 1 of 3 regimens: 50…

Read the full story

Friday, May 18, 2018

First Monoclonal Antibody Blocking CGRP Approved for Treatment of Migraine

The Food and Drug Administration today approved erenumab-aooe (Aimovig; Novartis, East Hanover, NJ) for prevention of migraine in adults. Erenumab is a monoclonal antibody that blocks the calcitonin g…

Read the full story

Friday, May 04, 2018

OnabotulinumtoxinA for Migraine Has Long-Term Safety and Efficacy

A wealth of results showing the long-term safety and efficacy of onabotulinumtoxinA (Botox; Allergan, Dublin, Ireland) for treating patients with migraine were presented at the recent American Academy…

Read the full story

Wednesday, May 02, 2018

Noninvasive, Cost-Effective Neuromodulation Therapy for Migraine and Cluster Headache

At the recent American Academy of Neurology meeting in Los Angeles, CA, electroCore, a commercial-stage bioelectronic medicine company, presented data from the PRESTO study of a hand-held noninvasive …

Read the full story

Sunday, April 22, 2018

Phase 3 Results for Ubrogepant for Treatment of Patients With Migraine

At the American Academy of Neurology meeting in Los Angeles, CA, researchers Joel Trugman, Michell Finnegan, Richard Lipton and others presented results from a phase 3 study on ubrogepant (Allergan, D…

Read the full story

Tuesday, April 17, 2018

Results from Phase 3 Trial of Erenumab for Migraine

Results were announced today from the phase 3b LIBERTY trial treating patients with migraine who have not had relief from 2 to 4 other treatment options with erenumab (provisionally approved as Aimovi…

Read the full story

Wednesday, March 07, 2018

Biomarkers Available to Speed Diagnosis of Fibromyalgia

Iquity (Nashville, Tennessee) has announced the release of IsolateFibromyalgia, an RNA analysis of blood samples, for the fast and accurate detection of fibromyalgia syndrome. IsolateFibromyalgia s…

Read the full story
Load More